Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LIXT

Lixte Biotechnology Holdings Inc

Apr 23 • 04:00PM ET

3.22

Dollar change -0.13
Percentage change -3.88	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.77	Insider Own	20.15%	Shs Outstand	2.25M	Perf Week	-8.00%
Market Cap	7.25M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.80M	Perf Month	46.33%
Income	-5.09M	PEG	-	EPS next Q	-	Inst Own	5.08%	Short Float	0.93%	Perf Quarter	49.77%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-71.59%	Short Ratio	0.03	Perf Half Y	35.86%
Book/sh	0.22	P/B	14.64	EPS next Y	-	ROA	-103.09%	Short Interest	0.02M	Perf Year	-51.06%
Cash/sh	1.87	P/C	1.73	EPS next 5Y	-	ROE	-111.07%	52W Range	1.58 - 9.50	Perf YTD	37.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-4.05%	ROI	-127.34%	52W High	-66.11%	Beta	-0.28
Dividend TTM	-	Quick Ratio	13.48	Sales past 5Y	0.00%	Gross Margin	-	52W Low	103.80%	ATR (14)	0.33
Dividend Ex-Date	-	Current Ratio	13.48	EPS Y/Y TTM	31.16%	Oper. Margin	0.00%	RSI (14)	52.61	Volatility	7.74% 12.63%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	53.17%	Payout	-	Rel Volume	0.07	Prev Close	3.35
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	564.02K	Price	3.22
SMA20	-1.73%	SMA50	15.62%	SMA200	19.49%	Trades		Volume	40,469	Change	-3.88%

Mar-27-24 08:30AM	NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES (GlobeNewswire) +56.10%
Mar-21-24 08:30AM	LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments (GlobeNewswire)
Feb-27-24 08:30AM	Professor Ren Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research (GlobeNewswire) +20.81%
Feb-26-24 08:30AM	LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI (GlobeNewswire)
Jan-29-24 08:30AM	First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial (GlobeNewswire) +8.04%
08:30AM	Loading…
Nov-13-23 08:30AM	LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations (GlobeNewswire)
Oct-16-23 08:30AM	LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration (GlobeNewswire) +9.54%
Oct-09-23 08:30AM	LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach (GlobeNewswire)
Sep-26-23 08:30AM	LIXTE Appoints Bas van der Baan as President and Chief Executive Officer (GlobeNewswire)
Sep-20-23 08:30AM	LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTEs First-in-Class PP2A Inhibitor, LB-100, Plus GSKs Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer (GlobeNewswire) +11.43%
Jul-20-23 04:05PM	LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -7.69%
Jul-18-23 08:00AM	LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -31.47%
Jul-17-23 08:30AM	Preclinical Results of LIXTE Biotechnologys Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTEs Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy (GlobeNewswire) +38.67%
Jun-23-23 08:30AM	LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
Jun-07-23 08:30AM	LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTEs Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas (GlobeNewswire) -9.42%
09:41AM	Loading…
Jun-05-23 09:41AM	Owning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's future (Simply Wall St.)
Jun-02-23 12:30PM	LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023 (GlobeNewswire)
May-30-23 08:30AM	Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnologys Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy (GlobeNewswire)
Apr-24-23 08:30AM	LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma (GlobeNewswire)
Apr-04-23 08:30AM	LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hopes Ongoing Phase 1b Clinical Trial in Evaluating Lixtes Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer (GlobeNewswire) +7.03%
Feb-14-23 01:50PM	LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH (GlobeNewswire) +10.28%
Feb-08-23 05:26AM	Is Lixte Biotechnology Holdings (NASDAQ:LIXT) In A Good Position To Invest In Growth? (Simply Wall St.) -33.33%
Feb-07-23 12:58PM	LIXTE Biotechnology Stock Jumps As Lead Program Shows Cancer Killing Activity In Animal Models (Benzinga) +133.10%
12:16PM	LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS (GlobeNewswire)
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-30-22 08:05AM	LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference (ACCESSWIRE) +14.20%
Oct-13-22 08:30AM	LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP (GlobeNewswire)
Jun-21-22 08:30AM	LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS (GlobeNewswire)
Jun-15-22 08:30AM	LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS (GlobeNewswire)
Apr-14-22 06:45PM	LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market (GlobeNewswire) -19.90%
02:54PM	Loading…
02:54PM	WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering (PR Newswire)
Apr-13-22 10:54AM	Lixte Biotechnology Holdings' (NASDAQ:LIXT) growing losses don't faze investors as the stock pops 73% this past week (Simply Wall St.) +6.52%
10:00AM	Healthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancers (GlobeNewswire)
09:00AM	WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (Business Wire)
08:30AM	WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (PR Newswire)
Apr-12-22 03:20PM	LIXT Stock Gets 200%+ Lift, Dont Get Caught on the Way Down (InvestorPlace) +67.27%
01:53PM	LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market (GlobeNewswire)
09:27AM	Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers (Benzinga)
08:30AM	LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations (GlobeNewswire)
Mar-22-22 08:30AM	Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnologys Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy (GlobeNewswire) -13.46%
Mar-16-22 08:30AM	LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference (GlobeNewswire) +10.00%
Jan-12-22 08:30AM	Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100 (GlobeNewswire) -6.52%
Jan-05-22 09:18AM	Lixte Biotechnology Stock Surges on Positive Data (Investing.com) +63.70%
08:30AM	Lixte Biotechnologys LB-100 Reported to Convert Immunologically Unresponsive (Cold) Tumors to Immunologically Responsive (Hot) Tumors (GlobeNewswire)
Nov-22-21 09:25AM	LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTES TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS (GlobeNewswire)
Oct-20-21 09:25AM	Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28 (GlobeNewswire) -5.24%
Oct-13-21 09:25AM	Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment (GlobeNewswire) -7.77%
Sep-24-21 09:31AM	We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-17-21 11:02AM	Lixte's LB-100 Blocks Behavioral Sensitization In Animal Models (Benzinga)
09:25AM	Lixte Biotechnologys LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction (GlobeNewswire)
Aug-03-21 09:25AM	LIXTE BIOTECHNOLOGYS LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY (GlobeNewswire)
Jul-22-21 09:25AM	LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM (GlobeNewswire)
Jul-13-21 09:25AM	Lixte Biotechnology Comments on Outside Research Citing LB-100s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer (GlobeNewswire)
Jul-07-21 09:35AM	Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021 (GlobeNewswire)
Jun-26-21 05:45AM	Need To Know: Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Insiders Have Been Buying Shares (Simply Wall St.)
Jun-03-21 08:22AM	A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100 (Benzinga)
Jun-02-21 09:35AM	Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer (GlobeNewswire)
May-18-21 05:30PM	Sidoti Microcap Virtual Conference (ACCESSWIRE) +14.59%
May-12-21 09:35AM	LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS (GlobeNewswire)
May-04-21 04:30PM	Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20 (GlobeNewswire) +6.18%
Apr-28-21 09:35AM	Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14 (GlobeNewswire) +13.62%
Apr-13-21 09:35AM	Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors (GlobeNewswire) -7.35%
Mar-17-21 09:35AM	Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24 (GlobeNewswire)
Mar-03-21 09:35AM	Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference (GlobeNewswire) -11.00%
Mar-02-21 06:38PM	WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) (Business Wire) -8.71%
03:40PM	WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (PR Newswire)
10:30AM	Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering (GlobeNewswire)
Mar-01-21 08:45AM	Lixte Biotechnology Announces $4.19 Million Registered Direct Offering (GlobeNewswire) -19.71%
Feb-26-21 11:58AM	LIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast Off (InvestorPlace) +48.01%
Feb-25-21 02:37AM	We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jan-19-21 09:35AM	Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixtes Lead Compound LB-100 to Treat Small Cell Lung Cancer (GlobeNewswire) +14.65%
Dec-01-20 03:28PM	WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc. (PR Newswire)
12:30PM	Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq (GlobeNewswire)
Nov-30-20 03:52PM	WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW) (Business Wire)
Nov-25-20 08:30AM	Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split (GlobeNewswire) -36.29%
Aug-18-20 09:35AM	The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixtes Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome (GlobeNewswire)
Jul-21-20 09:35AM	Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer (GlobeNewswire) -5.56%
Apr-30-20 10:30AM	Lixte Biotechnologys PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors (GlobeNewswire)

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
van der Baan Bastiaan Jeroen	President and CEO	Oct 03 '23	Buy	2.80	10,000	28,000	11,000	Oct 05 08:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIXT

Lixte Biotechnology Holdings Inc

Upgrade your FINVIZ experience